All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1400+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

Alnylam uses priority review voucher on vutrisiran (mutant and wild-type transthyretin targeting) as ATTR-CM competition heats up with BridgeBio’s recent approval
RNAi, transthyretin amyloid cardiomyopathy, priority review voucher - Read more

THE GOOD
Business Development

Gilead buys clinical stage HIV vaccine from partner Aelix Therapeutics
Vaccine, human immunodeficiency virus - Read more

Empyrean Therapeutics buys pre-IND asset EMS-312 (TLR-2 antagonist) from Eos Therapeutics
Small molecule, cancer - Read more

THE GOOD
Clinical Trial

Merck & Co.’s Winrevair Ph3 trial meets primary endpoint in PAH functional class III or IV patients at high risk of mortality
Fusion protein, pulmonary arterial hypertension - Read more

AstraZeneca’s Truqap (AKT inhibitor) delivers the Ph3 goods in prostate cancer subtype
Small molecule, prostate cancer - Read more

Cognition Therapeutics’ CT1812 (sigma-2 receptor complex antagonist) Ph2 biomarker analysis shows that molecule “may be preserving cognitive function and slowing disease progression“
Small molecule, Alzheimer’s disease - Read more

Blue Lake Biotechnology, CyanVac tout Ph2a data for CVXGA intranasal COVID-19 vaccine
Vaccine, COVID-19, intranasal delivery - Read more

Incyte’s promising Ph3 Monjuvi (anti-CD19) in follicular lymphoma
Monoclonal antibody, follicular lymphoma, cancer - Read more

PRESENTED BY YOU?
Get the attention of 1400+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

⬇️ More Good News ⬇️

THE GOOD
Company Launches

Advantage Therapeutics spins-off Klothea Bio to take on age-related disease R&D pipeline
mRNA, age-related disease, metabolic disease syndrome, cancer - Read more

THE GOOD
Fundraises

Adcendo $135M Series B, moving ADC candidates into the clinic
Antibody-drug conjugate, sarcoma, cancer - Read more

Kanglin Biotechnology $20M Series A, LVV-based gene therapy for beta thalassemia and sickle cell
Gene therapy, beta thalassemia, sickle cell disease, lentiviral vector - Read more

Replimune $140M upsized public offering
Oncolytic immunotherapy, cancer, herpes simplex virus (HSV) - Read more

BioSurfaces $2.0M grant from Bill and Melinda Gates Foundation
Cell therapy, drug delivery, implant - Read more

THE GOOD
IPOs

HanxBio plans Hong Kong exchange IPO to fund bispecific HX009 (PD-1/CD47 targeting) clinical ambitions
Bispecific antibody, biliary tract cancer - Read more

THE GOOD
Mergers & Acquisitions

Boston Scientific to acquire Intera Oncolocy
Small molecule, cancer, medical device, chemotherapy - Read more

Adragos Pharma acquires Baccinex
CDMO, fill-finish, injectables, lyophilization - Read more

Novo Holdings makes a “fishy” acquisition of aquaculture biotech Benchmark Genetics
Aquaculture, fish genetics - Read more

THE GOOD
Partnerships

GC Biopharma, Kanaph Therapeutics bispecific ADC development partnership
Bispecific antibody-drug conjugate, cancer, solid tumor - Read more

Evergreen Therapeutics, JUXIAN Pharmaceutical AI-enabled drug development partnership
Drug development, AI - Read more

THE GOOD
Patient Access

New transparency on 340B drug pricing shows benefits to clinics and safety net hospitals in Minnesota while pharma trade group PhRMA cries foul
340B drug pricing program, discount drug pricing - Read more

THE GOOD
Politics & Policy

President-elect Trump’s FDA commissioner pick is (mostly) well-received
Regulatory policy, political appointee - Read more [Paywall]

Some President-elect Trump picks might not be as radical as once thought, as former Warp Speed leader was approached for NIH position
National Institute of Health, political appointee - Read more [Paywall]

THE GOOD
Research

NIH publishes research on “TrialGPT” to help connect patients to clinical trials
Clinical trial recruitment, AI - Read more

Scribe Therapeutics touts pre-clinical data for CRISPR epigenetic silencing tech
CRISPR gene editing, cardiovascular disease - Read more 

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech🧬🦠🔬 

I’m offering this newsletter for free so it can get out to as many people as possible.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.*

*Best of all, it’s a work-related news source that you can likely expense. 😉 

THE BAD
Clinical Trials

To very little surprise, Cassava Sciences’ controversy-ridden simufilam (filamin A targeting) flunks in Ph3 trial, stock collapses
Small molecule, Alzheimer’s disease - Read more

Orbus Therapeutics eflornithine (ornithine decarboxylase blocking) misses primary efficacy endpoint in Ph3
Small molecule, astrocytoma, cancer - Read more

Biohaven’s taldefgrobep alfa (myostatin targeting) misses Ph3 endpoint in SMA, though may be a potential obesity treatment
Fusion protein, spinal muscular atrophy, obesity - Read more

THE BAD
Layoffs

Bristol Myers Squibb lays down additional job cuts at New Jersey R&D site
Research & development, early discovery - Read more

THE UGLY
Public Health

“I Ran Operation Warp Speed. I’m Concerned About Bird Flu.”
Infectious disease, H5N1 (bird flu), pandemic - Read more

Another reason that pasteurization is awesome - it helps you avoid the side helping of bird flu virus bits in your raw milk
Raw milk, H5N1 (bird flu) - Read more [Paywall]

THE UGLY
Withdrawals & Recalls

Lupin recalls 600k+ bottles of blood pressure med that (somehow) used an unapproved vendor’s API
Small molecule, hypertension - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here